Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74

1.

Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation.

Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T, McGlave P, Weisdorf D.

J Clin Pharmacol. 2007 Jan;47(1):6-12.

PMID:
17192496
2.

Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation.

Jacobson P, Rogosheske J, Barker JN, Green K, Ng J, Weisdorf D, Tan Y, Long J, Remmel R, Sawchuk R, McGlave P.

Clin Pharmacol Ther. 2005 Nov;78(5):486-500.

PMID:
16321615
3.

Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients.

Armstrong VW, Tenderich G, Shipkova M, Parsa A, Koerfer R, Schröder H, Oellerich M.

Ther Drug Monit. 2005 Jun;27(3):315-21.

PMID:
15905802
4.

Clinical pharmacokinetics of mycophenolate mofetil.

Bullingham RE, Nicholls AJ, Kamm BR.

Clin Pharmacokinet. 1998 Jun;34(6):429-55. Review.

PMID:
9646007
5.
6.

Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT).

Jacobson P, Huang J, Rydholm N, Tran M, Defor T, Tolar J, Orchard PJ.

J Clin Pharmacol. 2008 Apr;48(4):485-94. doi: 10.1177/0091270007313326. Epub 2008 Feb 22.

PMID:
18296555
7.

Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil.

Jain A, Venkataramanan R, Kwong T, Mohanka R, Orloff M, Abt P, Kashyap R, Tsoulfas G, Mack C, Williamson M, Batzold P, Bozorgzadeh A.

Liver Transpl. 2007 Jun;13(6):791-6.

8.

Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases.

Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM, Maloney DG, Storer B, Lange T, Chauncey T, Deininger M, Pönisch W, Anasetti C, Woolfrey A, Little MT, Blume KG, McSweeney PA, Storb RF.

Blood. 2003 Feb 15;101(4):1620-9. Epub 2002 Oct 3.

9.

Absorption characteristics of EC-MPS--an enteric-coated formulation of mycophenolic sodium.

Arns W, Gies M, Choi L, Zhu W, Cooper P, Yeh CM, Prasad P, Graf P, Schmouder R.

Int J Clin Pharmacol Ther. 2006 Aug;44(8):375-85.

PMID:
16961168
10.
11.

Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine.

Lobritto SJ, Rosenthal P, Bouw R, Leung M, Snell P, Mamelok RD.

Liver Transpl. 2007 Nov;13(11):1570-5.

12.

Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients.

Ensom MH, Partovi N, Decarie D, Dumont RJ, Fradet G, Levy RD.

Ther Drug Monit. 2002 Apr;24(2):310-4.

PMID:
11897977
14.

Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation.

Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Barón A, McSweeney PA.

Biol Blood Marrow Transplant. 2006 Feb;12(2):217-25.

15.

Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors.

Frymoyer A, Verotta D, Jacobson P, Long-Boyle J.

Br J Clin Pharmacol. 2013 Feb;75(2):463-75. doi: 10.1111/j.1365-2125.2012.04372.x.

16.

Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing.

Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E, Kliem C, Pulsipher M, Maziarz RT, McSweeney PA, Wade J, Langston AA, Chauncey TR, Bruno B, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2006 Apr;12(4):454-65.

17.

Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.

Tykodi SS, Warren EH, Thompson JA, Riddell SR, Childs RW, Otterud BE, Leppert MF, Storb R, Sandmaier BM.

Clin Cancer Res. 2004 Dec 1;10(23):7799-811.

18.

Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis.

Czock D, Rasche FM, Carius A, Glander P, Budde K, Bauer S, Keller F, von Müller L.

J Clin Pharmacol. 2007 Jul;47(7):850-9. Epub 2007 May 25.

PMID:
17526858
19.

A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Bemer MJ, Sorror M, Sandmaier BM, O'Donnell PV, McCune JS.

Cancer Chemother Pharmacol. 2013 Sep;72(3):607-18. doi: 10.1007/s00280-013-2232-8. Epub 2013 Aug 2.

20.

Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation.

Lange S, Mueller SC, Altmann S, Dahlhaus M, Drewelow B, Freund M, Junghanss C.

Bone Marrow Transplant. 2008 Apr;41(7):667-74. Epub 2007 Dec 17.

PMID:
18084333

Supplemental Content

Support Center